JBI-589

JBI-589 is a non-covalent PAD4 isoform-selective inhibitor. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors.


Cat. No.: EX-A8251	Purity: >98%

	Chemical structure of JBI-589

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
25mg	840	in_stock
50mg	1468	in_stock
100mg	2272	in_stock
250mg	4033	in_stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	2308504-22-3
Purity	>98%
Formula	C29H28FN5O
Mol Weight	481.5639
Color	Light yellow to yellow
State	solid powder
Solubility	DMSO : 100 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Deng H, et al. A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression. Cancer Res. 2022 Oct 4;82(19):3561-3572. [2]. Gajendran C, et al. Alleviation of arthritis through prevention of neutrophil extracellular traps by an orally available inhibitor of protein arginine deiminase 4. Sci Rep. 2023 Feb 23;13(1):3189.
CoA	CoA of JBI-589

Smiles:	CC1=C(C2=CC3=CC=CC=C3N2CC4=CC=C(F)C=C4)N=C5N1C=CC(C(N6C[C@H](N)CCC6)=O)=C5


		Search